Although survival in ovarian cancer remains poor, the use of paclitaxel and
interval debulking surgery are now recognized to prolong survival. Future
trials addressing the role of surgery, navel applications of chemotherapy,
and screening, along with care by recognized specialists, may well improve
outcome.